Functional Dyspepsia in the Elderly
AbstractPurpose of ReviewFunctional dyspepsia is a common condition, and the condition is defined by symptoms using Rome IV criteria. This review addresses the issue of functional dyspepsia in elderly patients, epidemiology, investigation, and treatment.Recent FindingsRecent studies show that while the prevalence of dyspepsia declines in the elderly, it is still prevalant investigations to confirm the diagnosis (including mandatory upper gastrointestinal endoscopy) must exclude organic disease. These include ulcers (particularly associated with nonsteroidal antiinflammatory drugs),Helicobacter pylori pathologies, cancer, coeliac disease, and autoimmune gastritis. Recent research is unraveling pathophysiology beyond symptom-only definitions, focusing on the duodenum with innate immune disturbance (duodenal eosinophilia) and microbial disruption as possible cause. Management of functional dyspepsia includes making a secure diagnosis, treatment with first-line proton pump inhibitors (PPI), then tricyclic antidepressants, and careful choice of prokinetics. Herbal treatments (peppermint oil) and STW-5 have in this age group limited efficacy.SummaryFurther studies are needed to define the prevalence of functional dyspepsia in the elderly and of prime importance, to exclude organic disease as a cause for symptoms of dyspepsia.
Conditions: Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Sta ge IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 Intervention: Drug: Fluorin...
Condition: Malignant Neoplasm Interventions: Drug: Fentanyl Sublingual Spray; Drug: Morphine; Other: Physical Performance Testing; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Conditions: D011471; D064129; D035683; D009360; D014408 Intervention: Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor: Azienda Ospedaliero-Universitaria Careggi Recruiting
Condition: Locally Advanced Colon Cancer Intervention: Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor: Universidad de León Recruiting
Condition: Patients With Metastatic Colorectal Cancer Interventions: Drug: Fluoropyrimidine; Drug: Bevacizumab Sponsor: Centre Hospitalier Universitaire Dijon Not yet recruiting
Condition: Breast Cancer Interventions: Drug: Avelumab; Drug: Aspirin; Drug: Lansoprazole Sponsors: The Christie NHS Foundation Trust; University of Manchester Not yet recruiting
Conditions: Nutrition; Physical Activity Interventions: Behavioral: Intervention Physical Activity; Other: Usual Care Sponsors: University of North Carolina, Chapel Hill; University of Texas Completed
Conditions: Neutropenia; Breast Cancer Interventions: Drug: Eflapegrastim; Drug: Docetaxel; Drug: Cyclophosphamide Sponsor: Spectrum Pharmaceuticals, Inc Not yet recruiting
Conditions: Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; Healthy Intervention: Sponsor: Indiana University Recruiting
Conditions: Neutropenia, Febrile; Leukemia; Pediatric Cancer; Antibiotic Reaction Interventions: Drug: Ceftazidime Injection; Drug: Cefepime Injection Sponsor: Indonesia University Completed